Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis

Sukrit Narula; Salim Yusuf; Michael Chong; Chinthanie Ramasundarahettige; Sumathy Rangarajan; Shrikant I Bangdiwala; Martin van Eikels; Kirsten Leineweber; Annie Wu; Marie Pigeyre; Guillaume Paré

doi:10.1016/S0140-6736(20)31964-4

Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis

Lancet. 2020 Oct 3;396(10256):968-976. doi: 10.1016/S0140-6736(20)31964-4.

Affiliations

¹ Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada; Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
² Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada.
³ Bayer, Leverkusen, Nordrhein-Westfalen, Germany.
⁴ Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada; Department of Medicine, Michael G DeGroote School of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
⁵ Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada; Department of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada. Electronic address: [email protected].

Abstract

Background: Angiotensin-converting enzyme 2 (ACE2) is an endogenous counter-regulator of the renin-angiotensin hormonal cascade. We assessed whether plasma ACE2 concentrations were associated with greater risk of death or cardiovascular disease events.

Methods: We used data from the Prospective Urban Rural Epidemiology (PURE) prospective study to conduct a case-cohort analysis within a subset of PURE participants (from 14 countries across five continents: Africa, Asia, Europe, North America, and South America). We measured plasma concentrations of ACE2 and assessed potential determinants of plasma ACE2 levels as well as the association of ACE2 with cardiovascular events.

Findings: We included 10 753 PURE participants in our study. Increased concentration of plasma ACE2 was associated with increased risk of total deaths (hazard ratio [HR] 1·35 per 1 SD increase [95% CI 1·29-1·43]) with similar increases in cardiovascular and non-cardiovascular deaths. Plasma ACE2 concentration was also associated with higher risk of incident heart failure (HR 1·27 per 1 SD increase [1·10-1·46]), myocardial infarction (HR 1·23 per 1 SD increase [1·13-1·33]), stroke (HR 1·21 per 1 SD increase [1·10-1·32]) and diabetes (HR 1·44 per 1 SD increase [1·36-1·52]). These findings were independent of age, sex, ancestry, and traditional cardiac risk factors. With the exception of incident heart failure events, the independent relationship of ACE2 with the clinical endpoints, including death, remained robust after adjustment for BNP. The highest-ranked determinants of ACE2 concentrations were sex, geographic ancestry, and body-mass index (BMI). When compared with clinical risk factors (smoking, diabetes, blood pressure, lipids, and BMI), ACE2 was the highest ranked predictor of death, and superseded several risk factors as a predictor of heart failure, stroke, and myocardial infarction.

Interpretation: Increased plasma ACE2 concentration was associated with increased risk of major cardiovascular events in a global study.

Funding: Canadian Institute of Health Research, Heart & Stroke Foundation of Canada, and Bayer.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Angiotensin-Converting Enzyme 2
Body Mass Index
Cardiovascular Diseases / blood*
Cardiovascular Diseases / mortality*
Case-Control Studies
Female
Humans
Male
Middle Aged
Peptidyl-Dipeptidase A / blood*
Risk Factors
Survival Rate

Substances

Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2